Peer-reviewed veterinary case report
High grade toxic side effects common with toceranib and lomustine
By Bavcar, S et al.·Published in Veterinary journal (London, England : 1997)·2017·Royal (Dick) School of Veterinary Studies, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study.
- Species:
- dog
Plain-English summary
A group of 10 dogs with advanced mast cell tumors (MCTs) were treated with a combination of toceranib, lomustine, and prednisolone. Unfortunately, all the dogs experienced severe side effects that required changes to their treatment plan, and three dogs died or were euthanized due to these complications. Despite these challenges, half of the dogs showed some improvement, and two dogs had a long-term positive response lasting over a year. This study suggests that while the combination treatment can work, it also carries significant risks that need to be managed carefully.
People also search for: dog mast cell tumor treatment · toceranib side effects in dogs · lomustine for dog cancer
Abstract
Mast cell tumours (MCTs) in dogs can present in a variety of forms. Non-resectable, recurrent or metastatic MCTs usually carry a poor prognosis and present a therapeutic challenge. Both toceranib and lomustine have shown single agent activity against MCTs in dogs. In this study, 10 dogs with advanced MCTs were enrolled prospectively and treated with toceranib (median dose 2.7mg/kg orally every other day), lomustine (median dose 60mg/morally every 3 weeks) and prednisolone (1mg/kg orally every other day, alternating with toceranib). Severe adverse events (SAEs), requiring alterations in the protocol, occurred in all dogs. The objective response rate was 50%. Three dogs died or were euthanased due to SAEs and therefore enrolment of new dogs was discontinued prematurely. A long term response (>1year) was observed in two dogs. Modifications of the protocol are required for future prospective studies.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28697868/